Relmada Therapeutics (NASDAQ:RLMD) initiated with Buy rating and $75 (73% upside) price target at Jefferies.
Biogen (NASDAQ:BIIB)
upgraded to Buy with a $360 (29% upside) price target at Canaccord
Genuity citing the potential FDA nod for aducanumab in Alzheimer’s.
Shares down 1% premarket.
Denali Therapeutics (NASDAQ:DNLI) upgraded to Buy with a $37 (50% upside) price target at Goldman Sachs. Shares up 1% premarket.
Intuitive Surgical (NASDAQ:ISRG) downgraded to Hold at Deutsche Bank. Shares down 3% premarket.
Medpace Holdings (NASDAQ:MEDP) downgraded to Hold with an $87 (1% downside risk) price target at SunTrust.
Mylan N.V. (NASDAQ:MYL) downgraded to Market Perform with a $24 (10% upside) price target at SVB Leerink. Shares down 4% premarket.
Tivity Health (NASDAQ:TVTY) downgraded to Neutral at Piper Sandler.
https://seekingalpha.com/news/3534642-canaccord-likes-biogen-in-premarket-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.